Hu Zhihuang, Zou Xuan, Qin Shanshan, Li Yuan, Wang Huijie, Yu Hui, Sun Si, Wu Xianghua, Wang Jialei, Chang Jianhua
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Transl Lung Cancer Res. 2020 Apr;9(2):325-336. doi: 10.21037/tlcr-20-513.
The coexistence of double primaries of lung cancer (LC) and breast cancer (BC) are not uncommon in women, but there has been limited research conducted of their molecular association. To decipher the internal pathogenesis of LC in patients with concurrent BC and LC, this study explored the clinical factors and relationship between hormone receptor (HR) expression and epidermal growth factor receptor (EGFR) gene mutation.
The clinicopathological characteristics of 400 female patients clinically diagnosed with double primary LC and BC at Fudan University Shanghai Cancer Center were collected. Pathological discrimination was performed to further confirm the double primaries in patients with available tissues. LC samples were then examined to detect EGFR gene mutation status by PCR-based assays and HR expression by immunohistochemistry (IHC). As a control cohort, the characteristics of 114 consecutive patients with LC only were compared with the double-primary patient group.
A total of 169 patients were pathologically confirmed with simultaneous LC and BC between January 2010 and October 2018. The dominant LC subtype was adenocarcinoma (ADC) (95.1%), and invasive ductal carcinoma (IDC) was the main BC subtype (71.0%). Synchronous and metachronous double primary BC-LC cases accounted for 39.1% and 60.9% of the patients, respectively. The absence of family cancer history was associated with a shorter interval between the two primary cancer diagnoses. Among 64 patients with EGFR mutations, 34.4% had HR-positive LC tissue, compared with 0/24 (0%) of those with EGFR wild-type LC (P<0.001). All of the patients with positive HR expression harbored an activating EGFR mutation (n=22); however, no correlation was observed in the control cohort.
Double primary BC-LC patients have distinctive clinicopathological features compared to those with LC only. The expression of HRs is significantly correlated with EGFR mutation status of LC tissues.
肺癌(LC)和乳腺癌(BC)双原发在女性中并不罕见,但关于它们分子关联的研究有限。为了解析同时患有BC和LC患者中LC的内在发病机制,本研究探讨了临床因素以及激素受体(HR)表达与表皮生长因子受体(EGFR)基因突变之间的关系。
收集了在复旦大学附属肿瘤医院临床诊断为双原发LC和BC的400例女性患者的临床病理特征。对有可用组织的患者进行病理鉴别以进一步确认双原发。然后通过基于PCR的检测方法检测LC样本中EGFR基因突变状态,并通过免疫组织化学(IHC)检测HR表达。作为对照队列,将114例连续的单纯LC患者的特征与双原发患者组进行比较。
2010年1月至2018年10月期间,共有169例患者经病理证实同时患有LC和BC。主要的LC亚型为腺癌(ADC)(95.1%),浸润性导管癌(IDC)是主要的BC亚型(71.0%)。同步和异时双原发BC-LC病例分别占患者的39.1%和60.9%。无家族癌症病史与两种原发癌诊断之间的间隔时间较短有关。在64例EGFR突变患者中,34.4%的患者LC组织HR呈阳性,而EGFR野生型LC患者中这一比例为0/24(0%)(P<0.001)。所有HR表达阳性的患者均存在EGFR激活突变(n=22);然而,在对照队列中未观察到相关性。
与单纯LC患者相比,双原发BC-LC患者具有独特的临床病理特征。HR的表达与LC组织的EGFR突变状态显著相关。